# Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes

> **NCT02081326** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 150 (estimated)

## Conditions studied

- Diabetes Mellitus, Type One
- Diabetes Mellitus, Type I
- Autoimmune Diabetes
- Covid19

## Interventions

- **BIOLOGICAL:** Bacillus Calmette-Guérin
- **BIOLOGICAL:** Saline injection

## Key facts

- **NCT ID:** NCT02081326
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-06
- **Primary completion:** 2029-07
- **Final completion:** 2031-07
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02081326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02081326, "Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02081326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*